Item 8.01 Other Events.
BioLineRx Ltd. (the “Company”)
announced today that on April 5, 2017 it closed its previously announced underwritten public offering of approximately 33.8 million
American Depositary Shares (“ADSs”), each representing one (1) of its ordinary shares, at a public offering price of
$0.85 per ADS. The Company received gross proceeds of $28.75 million, before deducting underwriting discounts and commissions and
estimated offering expenses payable by BioLineRx, which it expects to use to fund a number of clinical trials, including for BL-8040
and AGI-134, and for working capital and general corporate purposes. A copy of the press release announcing the closing of the
transaction is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In connection with the issuance of the
ADSs, on March 31, 2017, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with the
underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell the ADSs to
the Underwriters. For a complete description of the terms and conditions of the Underwriting Agreement, please refer to such agreement,
which is incorporated herein by reference and attached to this report as Exhibit 1.1.
On April 5, 2017, Yigal Arnon & Co.
issued its opinion, a copy of which is filed as Exhibit 5.1 to this report, with respect to the legality of the issuance by the
Company of the ordinary shares underlying the ADSs sold pursuant to the prospectus and the related prospectus supplement filed
by the Company with the U.S. Securities and Exchange Commission (“SEC”) on April 3, 2017.
On April 5, 2017, Morrison & Foerster
LLP issued its opinion, a copy of which is filed as Exhibit 5.2 to this report, with respect to the legality of the sale by the
Company of the ADSs sold pursuant to the prospectus and the related prospectus supplement filed by the Company with the SEC on
April 3, 2017.
Item 9.01 Financial Statements and Exhibits.
The following exhibits are filed as part
of this report:
||Description of Exhibit|
||Underwriting Agreement, dated March 31, 2017|
||Opinion of Yigal Arnon & Co., Israeli Counsel to the Company|
||Opinion of Morrison & Foerster LLP, U.S. Counsel to the Company|
||Press release dated April 5, 2017|